Micronized dHACM Injectable for the Treatment of Plantar Fasciitis (dHACM)
A Prospective, Single-Blinded, Randomized Controlled Trial of the Micronized dHACM Injection as Compared to the Saline Placebo Injection in the Treatment of Plantar Fasciitis
Sponsor: MiMedx Group, Inc.
Listed as NCT02427191, this PHASE2/PHASE3 trial focuses on Fasciitis, Plantar and remains completed. Sponsored by MiMedx Group, Inc., it has been updated 10 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Jul 2019 — Dec 2020 [monthly]
Completed PHASE2_PHASE3
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Aug 2018 — Jul 2019 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2_PHASE3
-
May 2017 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Mar 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MiMedx Group, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .